Medicines for Europe says that the sustainability of healthcare budgets in European nations has been “intensely pressured” in recent years by factors including an aging population and the introduction of high-cost drugs, and that governments aiming to address those challenges have resorted to austerity measures that have “driven the prices of some off-patent medicines to unsustainably low levels."
Medicines for Europe has released a new report, prepared by the Economist Intelligence Unit, that attempts to address the problem of medicine shortages in Europe.
In its introduction to the report, Medicines for Europe says that the sustainability of healthcare budgets in European nations has been “intensely pressured” in recent years by factors including an aging population and the introduction of high-cost drugs, and that governments aiming to address those challenges have resorted to austerity measures that have “driven the prices of some off-patent medicines to unsustainably low levels. This causes manufacturers of generic medicines to withdraw from the market, resulting in the increased risk of medicine shortages.”
The authors cite 2014 data showing that 86% of pharmacists surveyed (n = 607) in 36 European countries had experienced problems with sourcing medicines, and 66% said that medicine shortages occurred on a weekly or even a daily basis. The report’s authors state that the frequency and duration of medicine shortages has reached a point at which it has become imperative to address the issue that affects innovator, generic, and biosimilar medicines alike.
The report identifies the medicines most likely to be subject to shortages (which the authors define as a scenario that occurs when the supply of essential medicines is insufficient to meet public health and patient needs) as antimicrobials, oncology drugs, emergency drugs, cardiovascular drugs, and anesthetics. The European nations most affected by shortages were Denmark, the Netherlands, Portugal, and Croatia.
In addition to taking a toll on patients, whose outcomes can be affected by increased risk of medication errors with the use of unfamiliar, substituted treatments, shortages negatively affect pharmacists. The report cites 2013 data indicating that European pharmacists spend 2.5 to 5 hours per week looking for alternative treatments to medicines subject to shortages. Healthcare providers, too, face shortage-related burdens: some may be forced to switch patients’ treatments or even decide which patients to prioritize when rationing medications.
The report identifies economic causes for shortages of medicines:
It also addresses manufacturing and supply-chain issues:
Finally, the authors name regulatory lag time as an aggravating factor in resolving shortages.
Based on interviews with stakeholders (including national authorities, healthcare providers, pharmaceutical manufacturers, and patients) concerning these factors, the authors derived a set of key insights:
Other recommendations from some stakeholders included requiring manufactures to have more than 1 API supplier, giving pharmacists greater flexibility in substituting medicines, and standardizing packaging as a way to make the transport of medicines across borders more feasible.
The authors recommend the following strategies to avoid shortages:
While Medicines for Europe praised much of the report, it added several caveats. An emphasis on arriving at a common definition of shortages, the organization said, diverts the focus from understanding root causes of shortages. Furthermore, early-notification systems that do not address a lack of communication in the EU market will not go far enough to solve shortage issues. Finally, the group called suggestions to required manufactures to have more than 1 API supplier a potential driver of increased regulatory burdens. Greater regulatory efficiency, rather than increased regulatory requirements, it said, is key.
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.